SkinHealth Systems 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- SkinHealth Systems reported third quarter 2026 revenue of $69.2 million, down 2.1% year-over-year, toward the upper end of its $65 million-$70 million guidance range.
- Global consumables revenue was $50.4 million, up 1.2% year-over-year and approximately 73% of total revenue; delivery systems revenue was $18.8 million, down 9.9%.
- The company placed 798 systems, compared with 875 in the prior-year period, and average selling price was $23,509, down 1.2% year-over-year; global active systems grew to 37,342.
- Americas net sales were $48.9 million, up 1.4%, with consumables up 4.3%; EMEA net sales were $14.2 million, down 11.7%, and APAC net sales were $6.1 million, down 4.2%.
- GAAP gross margin was 68.2%, compared with 64.6% in the prior-year period, while adjusted gross margin was 71.8%, compared with 68% in Q3 2025.
- GAAP operating income was approximately $5 million, the second consecutive quarter of positive GAAP operating income, and net loss was approximately $0.9 million.
- Adjusted EBITDA was $13.4 million, or 19.3% of revenue, compared with $8.9 million, or 12.6%, in the prior-year period.
- Cash flow from operations was approximately $11.3 million and capital expenditure was approximately $1.1 million, resulting in free cash flow of approximately $10.2 million.
- SkinHealth Systems repaid the remaining $103.2 million principal amount of its 1.25% convertible senior notes due in 2026 on September 30th and ended the quarter with approximately $112.4 million in cash and cash equivalents.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
This call is being recorded on Thursday, November 5th, 2026. I would now like to turn the conference over to Norberto Aja, Investor Relations.
Thank you, operator, and good afternoon, everyone. Thank you for joining SkinHealth Systems' third quarter 2026 conference call. We released our results earlier this afternoon, which can be found on our corporate website at skinhealthsystems.com. Joining me on the call today is SkinHealth Systems President and Chief Executive Officer, Pedro Malha, along with our Chief Financial Officer, Mike Monahan. Before we begin, I want to remind everyone of the company's safe harbor language. Management may make forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including guidance and underlying assumptions. Forward-looking statements are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Listeners are cautioned not to place undue reliance on any forward-looking statements.
For a further discussion of risks related to our business, please refer to the risk factors contained in the company's filings with the Securities and Exchange Commission. In addition, this call will present non-GAAP financial measures. Management uses adjusted EBITDA and other non-GAAP measures as supplemental measures to evaluate operating performance and to facilitate period-to-period comparisons. These non-GAAP measures should be considered in addition to, and not as a substitute for, financial information prepared in accordance with GAAP. A reconciliation of these non-GAAP financial measures to the most comparable GAAP measure is available in the earnings press release, which was furnished to the SEC, as well as available on our website. Following management's prepared remarks, we will open the call for a question-and-answer session. With that, I would now like to turn the call over to our President and CEO, Pedro Malha.
Please go ahead, Pedro. Thank you, Norberto, and good afternoon, everybody.
Let me start with a central message from this quarter. We are making progress on the things that matter the most, stabilizing the Hydrafacial business and improving the economics of the company. At the same time, we are developing new opportunities for growth. To be clear, the work isn't done. Equipment sales remain challenging, particularly in EMEA, and utilization in our installed base is still below where it should be. But we are making good progress against our plan, and the third quarter results provide tangible evidence that we are operating from a stronger foundation than a year ago.
Our third quarter revenue was $69.2 million, towards the upper end of our $65 million-$70 million guidance range, meaning that our quarterly revenue declined 2.1% year-over-year, which is a meaningful improvement from the declines of 7.8% in the second quarter and 6.7% in the first quarter. Importantly, global consumables returned to growth, up 1.2% on a year-over-year comparison, while equipment remained the primary headwind. The rate of the overall revenue decline has moderated significantly. At the same time, the earnings profile of the business continues to improve. On a GAAP basis, gross margin was 68.2%, operating income was approximately $5 million, and net loss was approximately $1 million. We delivered positive GAAP operating income for the second consecutive quarter, and adjusted gross margin was 71.8%, our third consecutive quarter above 70%. Adjusted EBITDA was $13.4 million.
Some of our quarterly bottom line outperformance benefits from one-time item and expense timing, but we are also seeing the benefits of better margins, tighter cost management, and a more efficient operating model. The priority now is to sustain those improvements while returning revenue to growth. Looking across our regions, we are seeing encouraging signs in the Americas, which grew 1.4%, with consumables growing 4.3% on a year-over-year comparison. EMEA remained challenged, with revenues down approximately 12% on a year-over-year comparison, reflecting pressure in delivery systems, particularly in Germany, where execution has been below expectations. To address this, we have strengthened regional leadership, and we are taking actions to improve field execution and customer engagement. In APAC, revenue declined approximately 4% on a year-over-year comparison, primarily reflecting the transition in Australia and New Zealand to a distributor model.
While our performance varies across markets, we know where the pressure is, and we are taking actions to address it. Let me turn now to our three strategic priorities and the progress we are making in building a stronger, more sustainable growth business. Our first priority is strengthen the core Hydrafacial franchise. We have a fantastic global brand, a deep customer relationship, but we need to translate those advantages into better commercial execution. Over the past year, we organized our commercial teams, strengthened accountability, and invested in better training, processes, and selling tools. We are also taking a more targeted approach to customers, with a great emphasis on Hydrafacial clinical differentiators and the economic value it creates for providers. Additionally, we are expanding our relationships with corporate and multi-location accounts, where we see opportunities to broaden our installed base and increase treatment volumes.
During the quarter, we introduced a U.S. rental program to address one of the key barriers to equipment adoption, the upfront capital investment. It is still early, but the objective is to make Hydrafacial more accessible and bring more providers into the Hydrafacial ecosystem and support long-term relationships with them. We are also advancing our next-generation Hydrafacial platform, currently targeted for 2028, with the goal of improving clinical outcomes, provider workflow, and overall treatment experience. On competition, we have not seen a meaningful change in intensity from what we discussed last quarter. Our strategy is not simply to compete on price. It is to strengthen our differentiation, improve commercial execution, and deliver greater value to our providers. Our second strategic priority is getting more value from the Hydrafacial installed base. Throughout the years, we have built a substantial global network of providers, and that represents one of our biggest competitive advantage.
But placing a system is only the beginning of the customer relationship. The real opportunity lies in helping providers perform more treatments, increase utilization, and generate more recurring consumables revenue. We saw encouraging progress in the quarter, with global consumables growing 1.2% on a year-over-year comparison, and the Americas consumables returning to growth for the first time this year, supported by strong signature consumables performance, plus a HydraFacial relaunch and other commercial initiatives. But consumables revenues per systems remain below last year, and we believe we can do more to improve productivity across the install base. That is an important part of our innovation strategy, bringing providers clinically differentiated treatments that address real consumer needs and create more reasons for consumers to come back. So in September, we introduced our treatment enhancers, the HydraGlow Pre-Extraction Peel and the Hydralock HA Biocellulose Mask.
In October, we launched a new booster, HydraClear, for blemish-prone skin, which in clinical evaluation showed that a series of HydraClear treatments produce a 38% mean reduction in total blemishes. So these launches are a good example of the direction we are taking with innovation, more targeted, clinical-supported products that address specific customer needs. Our HydraScalp relaunch is another good example of how we are working to expand how providers can use their existing Hydrafacial system in the scalp and in the hair health. Equally important is our work in helping providers turn this innovation into greater treatment volumes, and we are doing this with education programs like Hydrafacial Impact, which was built to help providers attract more customers and increase repeat visits and improve their treatment economics. The point is not simply to launch more products. It is to make the systems already in the market more productive.
If we execute well, we can create a meaningful recurring revenue opportunity without relying entirely on new equipment placements. Our third strategic priority is to build a broader skin health business. Our ambition is not to be limited to one product or one category. We want to participate in attractive, high-growth segments of the aesthetic market and offer providers complementary treatments and give consumers more reasons to engage with our brands. SkinStylus is a good example of that strategy in play. Microneedling is an attractive and growing segment that complements Hydrafacial, and SkinStylus gives us a strong platform to compete in that market, offering both microneedling and nano-channeling treatments. SkinStylus consumables grew 39% year-over-year this quarter. Very recently, we expanded SkinStylus into six key European markets, leveraging our existing international commercial infrastructure.
We are also making good progress towards a planned introduction of another complementary device in 2027, with more details to come. But what is important strategically is that we believe we already have the customer relationships, the commercial infrastructure, and the clinical credibility that we can leverage those advantages across a broader portfolio. That is how we can build a stronger company, not by moving away from what made us successful, but by building on it. So let me bring all of this together. The revenue decline has narrowed significantly. Overall, consumables have returned to growth, margins are substantially stronger, and we are making progress on the commercial and innovation initiatives that can drive the next phase of our business. We still have work to do on the equipment sales, utilization, and EMEA. But when I look at SkinHealth Systems, I see a much bigger opportunity than the one we are capturing today.
We have a strong global brand, a substantial install base, a more efficient operating model, and an expanding portfolio. Our job now is to turn those advantages into sustainable growth through better execution in the core business, greater productivity from our install base, and a disciplined expansion into new categories. That is exactly what we are focusing on delivering. With that, I'll just turn the call over to Mike.
Thank you, Pedro. We are pleased with our company's performance this quarter. Our cross-functional teams were able to deliver on our revenue commitments, and we overperformed on driving adjusted EBITDA. The team was able to do this while continuing to invest in future growth initiatives. We're grateful for the hard work that everyone in this organization put into delivering. Thank you to the team. Total net sales in the third quarter were $69.2 million, down 2.1% compared with the prior year. This was primarily driven by decline in delivery system units sold year-over-year, partially offset by an increase in consumables revenue. Specifically, at the end of Q3, global active systems grew to 37,342. We continue to grow our footprint and provider reach each quarter. Q3 delivery systems revenue was $18.8 million, down 9.9%.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
